BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 182 filers reported holding BRIDGEBIO PHARMA INC in Q1 2022. The put-call ratio across all filers is 0.50 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,957 | +53.3% | 643 | 0.0% | 0.00% | – |
| Q2 2023 | $11,061 | +3.8% | 643 | 0.0% | 0.00% | – |
| Q1 2023 | $10,660 | +84.3% | 643 | -15.3% | 0.00% | – |
| Q4 2022 | $5,783 | -17.4% | 759 | +4.3% | 0.00% | – |
| Q3 2022 | $7,000 | 0.0% | 728 | 0.0% | 0.00% | – |
| Q2 2022 | $7,000 | +133.3% | 728 | +225.0% | 0.00% | – |
| Q1 2022 | $3,000 | +200.0% | 224 | +173.2% | 0.00% | – |
| Q4 2021 | $1,000 | -99.6% | 82 | -98.5% | 0.00% | – |
| Q3 2021 | $249,000 | -21.2% | 5,338 | +2.8% | 0.00% | – |
| Q2 2021 | $316,000 | -15.1% | 5,194 | -13.8% | 0.00% | – |
| Q1 2021 | $372,000 | +24.4% | 6,028 | +43.7% | 0.00% | – |
| Q4 2020 | $299,000 | +29800.0% | 4,196 | +11555.6% | 0.00% | – |
| Q3 2020 | $1,000 | 0.0% | 36 | -12.2% | 0.00% | – |
| Q2 2020 | $1,000 | – | 41 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 3,835,722 | $103,449,000 | 44.18% |
| Kohlberg Kravis Roberts & Co. L.P. | 36,900,661 | $995,211,000 | 12.26% |
| SC US (TTGP), LTD. | 2,544,738 | $68,632,000 | 4.69% |
| Cormorant Asset Management, LP | 2,780,885 | $75,000,000 | 4.31% |
| Perceptive Advisors | 6,706,268 | $180,868,000 | 4.15% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $717,968,000 | 3.22% |
| Hillhouse Capital Management | 2,035,790 | $54,905,000 | 1.75% |
| Alpine Group USVI, LLC | 20,000 | $539,000 | 1.70% |
| HHLR ADVISORS, LTD. | 2,352,900 | $63,458,000 | 1.42% |
| SCGE MANAGEMENT, L.P. | 588,235 | $15,865,000 | 0.79% |